Volume 23 Supplement 1
Nurses and the administration of Adrenaline in anaphylactic shock following the application of IV medicine
© Scheller and Posth. 2015
Published: 16 July 2015
"We recommend first-line treatment with intramuscular adrenaline before instituting other interventions as adrenaline is still underutilized in anaphylaxis although it is potentially lifesaving."
EAACI Guidelines Anaphylaxis 2014
How is reality in a Danish university hospital?
At Odense University Hospital, nurses take part in a simulation training in critical patient care for younger doctors. One of the scenarios used is anaphylactic shock after the application of IV antibiotics. 49 out of 50 nurses realized within the first two minutes, that the simulation patient suffered from anaphylaxis. 48 out of 50 nurses stopped the IV with the antibiotic. Often, oxygen and IV NaCl was administered, and thereafter the doctor, who was five minutes away was called. Only two out of 50 nurses primarily injected adrenalin according to the hospital guideline.
Because of this, in 48 out of 50 cases adrenalin was given after more than five minutes. According to Pumphrey (2000), the median for a deadly anaphylactic reaction after the IV administration of medication is five minutes. Adrenalin is according to EAACI Guidelines 2014 and ERC Guidelines 2010 the primary treatment for anaphylactic shock and the only treatment that is lifesaving in such a situation.
It is necessary for all nurses to receive training in anaphylactic shock, including the primary injection of adrenalin in order to secure immediate treatment in this critical condition.
This training could be linked to resuscitation training.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.